Amarin Corp Plcuk 8-K, filed Jul 18, 2023
Amarin Corp Plcuk (AMRN)
About this 8-K
Amarin Corp Plcuk filed this 8-K on July 18, 2023.
Items reported
- Item 2.02: Financial results
- Item 2.05: Exit or restructuring costs
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| Not applicable | ||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: +
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On July 18, 2023, Amarin Corporation plc (“Amarin” or the “Company”) issued a press release announcing its preliminary financial results for the three months ended June 30, 2023 (the “Press Release”). These financial results are based on preliminary information and management estimates for the three months ended June 30, 2023, are not a comprehensive statement of Amarin’s financial results, and are subject to completion of Amarin’s financial closing procedures. A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
| Item 2.05 | Costs Associated with Exit or Disposal Activities. |
On July 18, 2023, as described in the Press Release, Amarin announced that it was implementing a new organizational restructuring program (the “ORP”), resulting in the elimination and consolidation of certain roles across the organization, both in the United States and abroad, representing a reduction of the total Amarin employee base by approximately 30% from current levels. Management, with oversight and guidance of the Amarin board of directors (the “Board”), determined to implement the ORP following a review of Amarin’s business and to better position the organization for a new strategic focus. The Company expects these actions will reduce operating costs by approximately $40 million annually.
As part of the ORP, the Board promoted several members of the Company’s management team, including Tom Reilly, the Company’s Senior Vice President, Chief Financial Officer and Secretary (and principal financial and accounting officer), who was promoted to Executive Vice President, Chief Financial Officer & Head of Global HR (and principal financial and accounting officer), with an increased base salary amount of $560,000.
Amarin estimates that it will incur approximately $10 million in charges related to the ORP, substantially all of which are cash expenditures for one-time termination benefits and associated costs. Amarin expects to record the charges in the second quarter of 2023 and to make substantially all of the related payments by December 31, 2023.
| Item 5.02. | Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On July 18, 2023, Amarin appointed Patrick Holt to serve as the Company’s President and Chief Executive Officer (and principal executive officer), and as a member of the Board, effective July 18, 2023.
Mr. Holt most recently served as president of Cordis, Cardinal Health’s global interventional cardiovascular business and as member of Cardinal Health Inc’s global operating committee. In this role, Mr. Holt led a successful turnaround that included a return to revenue growth, a refocused R&D strategy, as well as sustained enhancements in operational effectiveness delivering margin expansion. Subsequently, he led the transaction process which culminated in the sale of Cordis to Hellman & Friedman in 2021 for an enterprise value in excess of $1 billion. He also previously served as president of Cardinal Health in Asia-Pacific. Prior to his time at Cardinal Health, he served in a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck. Mr. Holt is an independent non-executive director and audit committee member of Hugel, Inc., a publicly listed biopharmaceutical company and global leader in medical aesthetics. He earned a bachelor’s degree in biochemistry and chemistry from Monash University, Australia and is a graduate of Harvard Business School.
Upon Mr. Holt’s start date, Aaron Berg, who has been serving as the Company’s Interim President and Chief Executive Officer, will resume his role as Amarin’s Executive Vice President, President U.S. In light of Mr. Berg’s excellence and effectiveness in the interim role, the Board has awarded Mr. Berg a one-time cash bonus of $150,000.
The Company plans to file a subsequent Form 8-K with details on Mr. Holt’s compensation arrangements and other information required by Item 5.02 of Form 8-K.
Also on July 18, 2023, as a complement to the ORP, Amarin announced the implementation of a retention program for certain employees at various levels and among various organizations, which includes a cash component, payable in two tranches, with the first tranche payable in February 2024 (the “1st Installment”) and the second tranche payable in February 2025 (the “2nd Installment”), subject to the employee’s continued service with the Company. The eligible employees were also granted an option award, effective as of July 19, 2023, with an exercise price equal to the closing price of the American depositary shares representing the Company’s ordinary shares, as reported on the Nasdaq Global Market on such date, which vests as to 50% on January 1, 2024 and as to the remaining 50% on January 1, 2025. If an eligible employee is terminated without cause or resigns for good reason prior to the payment or vesting dates, as applicable, the cash awards (to the extent not yet paid) will become payable and the vesting on any unvested options shall accelerate, subject to the employee signing a customary release. Mr. Berg, Mr. Reilly and Steven Ketchum, Ph.D., Amarin’s President R&D and Chief Scientific Officer, were among the employees granted the retention awards and were granted the awards as follows:
| 1st Installment | 2nd Installment | Option Shares | ||||||||||
| Aaron Berg |
$ | 142,326 | $ | 142,326 | 404,400 | |||||||
| Tom Reilly |
$ | 136,500 | $ | 136,500 | 404,400 | |||||||
| Steven Ketchum |
$ | 161,460 | $ | 161,460 | 404,400 | |||||||
| Item 7.01 | Regulation FD Disclosure. |
On July 18, 2023, Amarin issued a second press release announcing the appointment of Mr. Holt. Amarin’s press release is furnished herewith as Exhibit 99.2 to this report.
The information in this report furnished pursuant to Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Exchange, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.
Forward-Looking Statements
This report contains forward-looking information about Amarin within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including statements related to the Company’s preliminary financial results, the ORP, the Chief Executive Officer roles, retention matters and business plans and are forward-looking statements, which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. These forward-looking statements are not promises or guarantees. Among the factors that could cause actual results to differ materially from those described herein include the Company’s ability to generate sufficient revenues and cash from sales of Vascepa and to retain sufficient talent to successfully execute on the Company’s plans, including following implementation of the ORP, the risk that the ORP will not produce the expected benefits and cost savings, as well as those risks and uncertainties described in Amarin’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission from time to time, including its most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and its upcoming Form 10-Q for the quarter ended June 30, 2023. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this Current Report, whether as a result of new information, future events or circumstances or otherwise.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated July 18, 2023 (furnished herewith) | |
| 99.2 | Press Release, dated July 18, 2023 (furnished herewith) | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 18, 2023 | Amarin Corporation plc | |||||
| By: | /s/ Tom Reilly | |||||
| Tom Reilly | ||||||
| Chief Financial Officer | ||||||
Exhibit 99.1
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient
Access to VASCEPA®/VAZKEPA® Globally
— Focus on Gaining Access for European Patients in Remaining Geographies and Strategic Use of Commercial Resources —
— Maximizes Cash Flow Opportunity Through Streamlined Model in U.S. —
— Company Expects Restructuring to Drive Annual Cost Savings of Approximately $40 Million —
— Announces Preliminary Earnings Results for Second Quarter 2023 —
— Company to Host Conference Call Today at 5:00 p.m. EDT —
DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 — Amarin Corporation plc (NASDAQ: AMRN) today announced that it has initiated an organizational restructuring program to right-size and strengthen the Company to enhance shareholder value.
Over the last several months, the new Amarin Board of Directors and senior management team have conducted a comprehensive review of the business. VASCEPA®/VAZKEPA® is supported by a wealth of clinical data and backed by strong science that can benefit patients around the world. Amarin continues to generate revenue in the U.S. and maintains a strong cash position. However, the restructuring announced today reflects the need for a thoughtful and significant change in strategy given the Company’s size, resources and challenging operating environment. The Company expects these actions will reduce operating costs by approximately $40 million annually.
Amarin’s refocused strategic priorities and restructuring plan focuses on three core areas:
| • | Maximizing U.S. Cash Flow Through Streamlined Model: Amarin will maintain VASCEPA as a cost-effective option to generics while implementing a reduction in force of all U.S. sales force positions and approximately 30% of non-sales roles. Amarin will retain its managed care and trade organization to support these efforts. The Company will continue to explore innovative approaches to driving revenue as well as the timing of an authorized generic version of VASCEPA to maintain its leadership position in the icosapent ethyl (IPE) market. |
| • | European Redesign: Amarin will redesign its commercial infrastructure in Europe to better align with pricing and reimbursement status, commercial potential and progress to date, as well as streamline certain cross-geographic functions and better leverage learnings across countries. In addition, Amarin will continue to advance its pricing and reimbursement activities to drive access in remaining geographies, including those where progress has been delayed. |
| • | Expanding Upon International Partnerships: Amarin will work on generating revenue from its partnerships in key international markets, including Canada, MENA, China and Australia / New Zealand, and will continue to explore additional partnerships. |
“A thorough review confirmed our belief in the inherent value of Amarin and the need for change when it comes to managing the business for value creation,” said Odysseas Kostas, M.D., and Chairman of the Board. “The actions we have taken since joining the Board reflect our ongoing efforts to turn around the company. The organizational restructuring and our new CEO hire announced today will support those strategic efforts. Our focus continues to be bringing VASCEPA/VAZKEPA to high-risk patients and generating value for Amarin shareholders as we execute against this strategy.”
“We are grateful for the efforts and commitments of our impacted colleagues who have worked tirelessly to advance our mission in the U.S. and globally,” said Aaron Berg, Amarin’s Interim President and CEO. “These are difficult, but necessary decisions to best position Amarin for the future and ensure we can give millions of patients globally the opportunity to access VASCEPA/VAZKEPA. We maintain strong conviction around VASCEPA/VAZKEPA, which is supported by a wealth of clinical data and backed by strong science, particularly the results of the REDUCE-IT trial and its impact on cardiovascular outcomes, which clearly underscore the product’s value in addressing a significant unmet need to reduce major adverse cardiovascular events in high-risk patients.”
Preliminary Q2 2023 Earnings Results
In connection with today’s announcement, Amarin also announced preliminary unaudited financial results for the second quarter of 2023, including product revenue of approximately $65 million compared to $85 million in the first quarter of 2023. For the quarter, the Company had positive cash flow of $9 million, which includes a $5 million milestone payment following the recent VHTG regulatory approval in China. The second quarter end cash position was $313 million versus $304 million at the end of the first quarter. Further details will be discussed on today’s conference call.
“In the second quarter, we maintained our U.S. prescription volume for VASCEPA and our overall cash position is positive,” Mr. Berg said. “However, our product revenue was impacted by increasing net pricing pressure and other inter-quarter variability in the U.S. and we also saw slower than expected revenue materialization and pricing and reimbursement access in Europe. As a result, we are taking decisive and significant actions to realign our business, which will maximize our strong cash position while putting us on the right path to enhance shareholder value.”
Conference Call and Webcast Information
Amarin will host a conference call on July 18, 2023, at 5:00 p.m. EDT to discuss this announcement and the Company’s preliminary financial results. The conference call can be accessed on the investor relations section of the Company’s website at www.amarincorp.com, or via telephone by dialing 888-506-0062 within the United States, 973-528-0011 from outside the United States, and referencing conference ID 897730. A replay of the call will be made available for a period of one week following the conference call. To listen to a replay of the call, dial 877-481-4010 from within the United States and 919-882-2331 from outside of the United States, and reference conference ID 48709. A replay of the call will also be available through the Company’s website shortly after the call.
In light of the call scheduled for today, Amarin will release its full second quarter 2023 financial results on August 2, 2023, but will not hold a conference call at that time.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin is committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of U.S. securities laws, including, but not limited to, expectations regarding Amarin’s financial performance, metrics, and initiatives, including its 2023 revenues, operating expenses, supply purchases, negotiations and settlements, product prescriptions and managed care coverage, continued savings from cost-cutting initiatives that is currently exceeding initial targets, and Amarin’s overall ability to continue to deliver stable revenues and cash position from its U.S. business; beliefs about the timing and outcome of international commercial partnerships, regulatory filings, reviews, recommendations, approvals, and related reimbursement decisions and commercial launches of VASCEPA/VAZKEPA outside of the U.S.; beliefs that Amarin’s current resources are sufficient to fund projected operations; and beliefs about the overall world-wide market potential and success of VASCEPA/VAZKEPA generally. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s most recent quarterly report on Form 10-Q for the quarter ended March 31, 2023. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (amarincorp.gcs-web.com), including but not limited to investor presentations and investor FAQs, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Jordan Zwick
Amarin Corporation plc
IR@amarincorp.com
Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com
Exhibit 99.2
Amarin Appoints Patrick Holt as President and Chief Executive Officer
DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 – Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. Aaron Berg, who served as Interim President and CEO since April 2023, will remain with the Company in a senior leadership role.
Mr. Holt brings more than 25 years of leadership in the life sciences industry and significant international operating experience. He most recently served as president of Cordis, Cardinal Health’s global interventional cardiovascular business where he led a turnaround of the business, followed by a transaction process which led to its successful sale. Mr. Holt previously held a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck.
“We are excited to welcome Pat as our new CEO,” said Odysseas Kostas, M.D., the Chairman of the Board. “Pat’s international and cardiovascular business experience and track record of turnaround success are exactly what the Company needs at this critical time. The Board looks forward to working with Pat to continue to put Amarin on the best path to maximizing shareholder value.”
Mr. Holt said, “The science at Amarin is compelling and aligned to a significant unmet need, and VASCEPA®/VAZKEPA® maintains meaningful untapped value given its clinical profile and proven cardiovascular risk reduction and outcomes. Decisive action is needed to realize Amarin’s full potential, and alongside the entire Amarin team, I am committed to realizing the opportunities inherent in the business to maximize value for patients, physicians, payors and shareholders. I look forward to working with the Board and leadership team as we evaluate and execute on all opportunities to enhance value.”
Dr. Kostas concluded, “On behalf of the Board, I want to thank Aaron for stepping up to lead when he did, working tirelessly over the last few months toward strengthening the Company’s global operations. We look forward to him continuing to contribute in an important way at Amarin.”
About Patrick Holt
Patrick Holt most recently served as president of Cordis, Cardinal Health’s global interventional cardiovascular business and as member of Cardinal Health Inc’s global operating committee. In this role, Mr. Holt led a successful turnaround that included a return to revenue growth, a refocused R&D strategy, as well as sustained enhancements in operational effectiveness delivering margin expansion. Subsequently, he led the transaction process which culminated in the sale of Cordis to Hellman & Friedman in 2021 for an enterprise value in excess of $1 billion. He also previously served as president of Cardinal Health in Asia-Pacific. Prior to his time at Cardinal Health, he served in a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck. Mr. Holt is an independent non-executive director and audit committee member of Hugel, Inc., a publicly listed biopharmaceutical company and global leader in medical aesthetics. He earned a bachelor’s degree in biochemistry and chemistry from Monash University, Australia and is a graduate of Harvard Business School.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin is committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of U.S. securities laws, including, but not limited to, expectations regarding Amarin’s financial performance, metrics, and initiatives, including its 2023 revenues, operating expenses, supply purchases, negotiations and settlements, product prescriptions and managed care coverage, continued savings from cost-cutting initiatives that is currently exceeding initial targets, and Amarin’s overall ability to continue to deliver stable revenues and cash position from its U.S. business; beliefs about the timing and outcome of international commercial partnerships, regulatory filings, reviews, recommendations, approvals, and related reimbursement decisions and commercial launches of VASCEPA/VAZKEPA outside of the U.S.; beliefs that Amarin’s current resources are sufficient to fund projected operations; and beliefs about the overall world-wide market potential and success of VASCEPA/VAZKEPA generally. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s most recent quarterly report on Form 10-Q for the quarter ended March 31, 2023. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (amarincorp.gcs-web.com), including but not limited to investor presentations and investor FAQs, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Jordan Zwick
Amarin Corporation plc
IR@amarincorp.com
Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com